Abstract
Background/Objective SeptiCyte RAPID is a transcriptional host response assay that discriminates between sepsis and non-infectious systemic inflammation (SIRS) with a one-hour turnaround time. The overall performance of this test in a cohort of 419 patients has recently been described [Balk et al., J Clin Med 2024, 13, 1194]. In this study we present results from a detailed stratification analysis in which SeptiCyte RAPID performance was evaluated in the same cohort across patient groups and subgroups encompassing different demographics, comorbidities and disease, sources and types of pathogens, interventional treatments, and clinically defined phenotypes. The aims were to identify variables that might affect the ability of SeptiCyte RAPID to discriminate between sepsis and SIRS, and to determine if any patient subgroups appeared to present a diagnostic challenge for the test.
Methods 1) Subgroup analysis, with subgroups defined by individual demographic or clinical variables, using conventional statistical comparison tests. 2) Principal component analysis and k-means clustering analysis, to investigate phenotypic subgroups defined by unique combinations of demographic and clinical variables.
Results No significant differences in SeptiCyte RAPID performance were observed between most groups and subgroups. One notable exception involved an enhanced SeptiCyte RAPID performance for a phenotypic subgroup defined by a combination of clinical variables suggesting a septic shock response.
Conclusions We conclude that for this patient cohort SeptiCyte RAPID performance was largely unaffected by key variables associated with heterogeneity in patients suspected of sepsis.
Competing Interest Statement
K.N., T.D.Y., D.S., J.T.K., S.C., R.F.D. and R.B.B. declare they are present or past employees or shareholders of Immunexpress, Inc. X.W.M. declares that she is a present employee of Princeton Pharmatech, Inc. R.R.M. III discloses that, over the time period of relevance to this work he was paid (as a consultant) an honorarium by Immunexpress for conducting a critical review of a Clinical Evaluation Report of SeptiCyte technology, submitted by Immunexpress to the Therapeutic Goods Administration (TGA) of Australia. N.R.A. declares that he has received grants from the NIH and Department of Defense for non-related work, and that payments from these grants are made to his institution, the University of Colorado. N.R.A. also declares that he is a committee member of the Pfizer Paxlovid US Medical Advisory Committee formed to broadly discuss COVID-19 related therapeutic priorities and populations of interest. B.K.L. declares that he is a consultant for Karius Inc., is a member of the Scientific Advisory Board for Seegene Inc., and has received honoraria for speaking for Qiagen Inc. No other competing interests are declared.
Funding Statement
This work was funded by Immunexpress, Inc.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics approval for the MARS trial was given by the medical ethics committee of AMC, Amsterdam (approval # 10-056C, 16 June 2010). Ethics approvals for the VENUS trial were given by the relevant Institutional Review Boards as follows: Intermountain Medical Center/Latter Day Saints Hospital (approval # 1024931, 21 January 2014); Johns Hopkins Hospital (approval # IRB00087839, 28 January 2016); Rush University Medical Center (approval # 15111104-IRB01, 11 March 2016); Loyola University Medical Center (approval # 208291, 10 March 2016); Northwell Healthcare (approval #16-02-42-03, 1 April 2016). Ethics approvals for the NEPTUNE trial were given by the relevant Institutional Review Boards as follows: Emory University (approval # IRB00115400, 3 December 2019); Grady Memorial Hospital (approval # 00-115400, 14 January 2020); Rush University Medical Center (approval # 19101603-IRB01, 16 January 2020); University of Southern California Medical Center (approval # HS-19-0884-CR001, 10 February 2020). All methods used in this study were carried out in accordance with the relevant guidelines and regulations. Informed Consent Statement: All subjects, or their legally authorized representatives, gave informed consent for participation in this study.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Updated affiliation and email address for Franco R D Alessio (author 9). Name correction for Xue W Mei (author 26). Updated conflicts of interest statement. Updated author contributions statement. Reformatted all references and added DOIs where missing. References now numbered consecutively as they appear in manuscript.
Data Availability
The datasets used and/or analyzed during the current study are available from the corresponding author upon reasonable request.
